Alaunos Therapeutics (TCRT) Capital Expenditures (2009 - 2025)

Alaunos Therapeutics' (TCRT) quarterly Capital Expenditures came in at $1000.0 in Q4 2025, little changed on a QoQ basis from $1000.0 in Q3 2023.

Alaunos Therapeutics (TCRT) Capital Expenditures (2009 - 2025) Analysis & Trends

Alaunos Therapeutics (TCRT) has 16 years of Capital Expenditures data on file, last reported at $1000.0 in Q4 2025.

Quarterly Capital Expenditures changed N/A year-over-year to $1000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1000.0 (changed N/A YoY) and the FY2025 annual result came in at $98000.0, changed N/A from the prior year.
Capital Expenditures held at $1000.0 in Q4 2025, from $1000.0 in the prior quarter.
In the past five years, Capital Expenditures ranged from a high of $3.0 million in Q4 2021 to a low of -$1.2 million in Q2 2021.
A 4-year average of $301000.0 and a median of $76000.0 in 2022 frame the typical range for Capital Expenditures.
The widest YoY moves for Capital Expenditures: up 1903.03% in 2021, down 329.04% in 2021.
Tracing TCRT's Capital Expenditures over 4 years: stood at $3.0 million in 2021, then slumped by 92.54% to $222000.0 in 2022, then tumbled by 99.55% to $1000.0 in 2023, then changed by 0.0% to $1000.0 in 2025.
The last three Capital Expenditures figures came in at $1000.0 (Q4 2025), $1000.0 (Q3 2023), and $95000.0 (Q2 2023), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capex (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	112.20 Mn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	240.20 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	37.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	25.02 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	34.68 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-73.57 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	6.26 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	251.02 Mn
10	Alaunos Therapeutics	4.28 Mn	4.16 Mn	-	-

Download Data